Pulmonary Arterial Hypertension

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

Orenitram Decreased Risk of Morbidity/Mortality Event in PAH Trial

By

FREEDOM-EV was an international, multicenter, randomized, double-blind, placebo-controlled trial (N=690) that randomized patients to 3 daily doses of Orenitram or placebo.

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

Generic Version of Adcirca Now Available for Pulmonary Arterial Hypertension

By

Tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, is indicated to treat pulmonary arterial hypertension to improve exercise ability.

Implantable System for Remodulin Approved for Patients With PAH

Implantable System for Remodulin Approved for Patients With PAH

By

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension.

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

Supplementing Pulmonary Arterial Hypertension Therapy With Nutritional Changes

By

Current research suggests patients with pulmonary arterial hypertension may benefit from iron and vitamin D supplementation.

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

PAH Mortality Rates Comparable With ERA or PDE5 Inhibitor Therapy

By

There were no significant differences in pulmonary arterial hypertension survival based on therapy type, age was an important modifier.

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

Pulmonary Arterial Stiffness Related to mPAP and Heart Rate in Idiopathic PAH

By

Pulmonary arterial stiffness was related to mean pulmonary arterial pressure and heart rate in patients with untreated idiopathic pulmonary arterial hypertension.

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

RV Base/Apex Ratio May Help Diagnose Pulmonary Arterial Hypertension in Children

By

Right ventricular base/apex ratio reference values may help clinicians diagnose children with pulmonary arterial hypertension.

Improved Counseling Needed in Pregnant Patients With Pulmonary Arterial Hypertension

Improved Counseling Needed in Pregnant Patients With Pulmonary Arterial Hypertension

By

Many healthcare providers reported that they often do not have the time to counsel their patients with pulmonary arterial hypertension on pregnancy risks.

PAH in Congenital Heart Disease: Expert Q&A on Challenges and Advances

PAH in Congenital Heart Disease: Expert Q&A on Challenges and Advances

By

Management strategies were discussed for subtypes of PAH-congenital heart disease including Eisenmenger syndrome, PAH with persistent systemic to pulmonary shunts, and PAH with small or coincidental defect or PAH after defect closure.

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

Improving Risk Stratification, Diagnostic Accuracy in PAH With Cardiopulmonary Exercise Testing

By

Cardiopulmonary exercise testing can be an important diagnostic and prognostic tool in pulmonary arterial hypertension.

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

Sildenafil, Bosentan Combination vs Sildenafil Monotherapy in SSc-Associated PAH

By

There was no significant difference in efficacy between sildenafil and bosentan initial combination therapy and sildenafil monotherapy in patients with systemic sclerosis-related pulmonary arterial hypertension.

Arrhythmia Associated With Higher Mortality in Congenital Heart Disease-Related PAH

Arrhythmia Associated With Higher Mortality in Congenital Heart Disease-Related PAH

By

Arrhythmia was a significant predictor of mortality in adult patients with congenital heart disease and pulmonary arterial hypertension.

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

Brain Natriuretic Peptide Shows Promise as Biomarker in Group 1 PAH

By

There was a significant relationship between brain natriuretic peptide levels and mortality in patients with group 1 pulmonary arterial hypertension.

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

Connective Tissue Diseases in Comorbid PAH: A Case for Separating SSc, SLE

By

Recent evidence suggests that systemic sclerosis and systemic lupus erythematosus comorbid with pulmonary arterial hypertension should be considered separate diseases.

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

Pulmonary Hypertension Has Adverse Effect on Post-Lung Transplant Survival

By

The 1-year survival rate after lung transplantation in patients with a mean pulmonary arterial pressure ≥25 mm Hg was lower than the survival rate of those with a mean pulmonary arterial pressure <25 mm Hg.

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

Improved Pulmonary Arterial Hypertension Risk Prediction Tools Needed

By

The use of a risk calculator aimed at achieving a low-risk profile in PAH trials is discussed.

PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones

PAH Risk, Mortality Increased by Disturbances in Male Sex Hormones

By

Men with higher estradiol and estradiol/testosterone levels had an increased risk for pulmonary arterial hypertension.

AHA: Right-Sided Heart Failure Evaluation, Management Guidelines

AHA: Right-Sided Heart Failure Evaluation, Management Guidelines

By

The American Heart Association scientific statement offers recommendations on right-sided heart failure regarding physical examination, serum markers, and imaging.

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

Serum Chloride Linked With Survival in Pulmonary Arterial Hypertension

By

Serum chloride was a strong and independent predictor of mortality at 6 months after a pulmonary arterial hypertension diagnosis.

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

Predictive Value of Idiopathic PAH Risk Assessment Using Comorbidities, Age

By

Ischemic heart disease and kidney dysfunction were identified as 2 comorbidities that may affect outcomes in idiopathic pulmonary arterial hypertension.

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

Stem Cell Therapy for RV Failure in PAH: Overview and Clinician Interview

By

Stem cell therapy targeting right ventricular failure may help improve pulmonary circulation in pulmonary arterial hypertension.

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

Opsumit sNDA Submitted for Chronic Thromboembolic Pulmonary Hypertension

By

The sNDA is accompanied by results from the MERIT-1 trial, a Phase 2 randomized, placebo-controlled, double-blind study which assessed the efficacy, safety and tolerability of macitentan 10mg in 80 patients with inoperable CTEPH.

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

Pulmonary Arterial Hypertension Prognosis Linked to Walking Distance

By

Walking a distance of >400 meters in the 6-minute walk test was associated with a reduced risk for pulmonary arterial hypertension-related death or hospitalization.

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

Benefits of Targeted Pharmacologic Therapy in PAH and Distal CTEPH

By

In patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, targeted pharmacologic treatment was associated with an increase in achieved therapeutic goals.

Perioperative Risk Assessment in a Patient With COPD

Perioperative Risk Assessment in a Patient With COPD

By

A 64-year-old man with chronic obstructive pulmonary disease, diabetes, chronic kidney disease, and morbid obesity seeks preoperative approval for femoral popliteal bypass surgery.

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

Pulmonary Arterial Hypertension Outcomes With Atrial Arrhythmia

By

Increased right atrial and pulmonary wedge pressures and increased thyroid disease prevalence were associated with atrial arrhythmia development in idiopathic or systemic sclerosis-related pulmonary arterial hypertension.

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

Oral Treprostinil Dosing Characteristics in Pulmonary Arterial Hypertension

By

Prescribers tend to favor a frequency of 3 times per day for oral treprostinil dosing in patients with pulmonary arterial hypertension.

Pulmonary Hypertension Outcomes Predicted by NT-pro BNP

Pulmonary Hypertension Outcomes Predicted by NT-pro BNP

By

N-terminal-pro brain natriuretic peptide may be a useful biomarker for both mortality and respiratory exacerbations in pediatric patients with pulmonary hypertension.

Clinical Case: Pregnant Woman Presents With Worsening Dyspnea

Clinical Case: Pregnant Woman Presents With Worsening Dyspnea

By

A 32-year-old woman presents to the emergency department with complaints of dyspnea on exertion and near syncopal episodes.

PDE-5 Inhibitor Prescribing Trends Do Not Meet Pulmonary Hypertension Guidelines

PDE-5 Inhibitor Prescribing Trends Do Not Meet Pulmonary Hypertension Guidelines

By

Nearly two-thirds of phosphodiesterase-5 inhibitor prescriptions are inconsistent with pulmonary hypertension guidelines.

Sign Up for Free e-Newsletters